A fragile and complex global supply chain leaves heparin vulnerable to disruption, prompting urgent calls for diversification, regulatory clarity, and investment in synthetic alternatives.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.